Company founder Dr. Fritz Wörwag has developed the active ingredient benfotiamine further and it became a milestone in the therapy of diabetic comorbidities. With its high bioavailability, it significantly contributes to protect against vitamin B1 deficiency.
International clinical studies, meetings of experts, and symposia, plus close collaboration with research labs: We invest in science and clinical research so we can develop the best possible medications for our patients.